Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-12-01

Summary

This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.

• Phase: PHASE1

Details

• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Treatments: Gemcitabine; Injections; Paclitaxel; penpulimab